8:00 am Registration & Morning Coffee Networking

Synopsis

  • Live Demo in Virtual Exhibition Area
  • 1-1 Meetings

9:00 am Opening Remarks

9:10 am FDA Insight: Utilizing 3D Models to Drive Drug Development & Regulatory Acceptance

  • Suzanne Fitzpatrick Senior Advisor for Toxicology Center for Food Safety and Applied Nutrition , U.S Food and Drug Administration (FDA)

Synopsis

  • Outlining the latest developments to incorporate 3D model data to support translational success
  • Addressing the evidence required to advance drug candidates from preclinical 3D studies into phase I clinical trials
  • The need to adapt guidelines, define context of use across the model continuum and using 3D systems to support in vivo evidence

9:30 am Human Intestinal Organoids to Study the Gut Endocrine Cells

Synopsis

  • Genetic engineering of human intestinal organoids to produce and fluorescently track hormone-producing cells
  • Employing these organoids to perform an in-depth analysis of gut endocrine cells, uncovering therapeutic targets for metabolic diseases

9:50 am The Development & Application of 3D Culture Techniques to Construct Models of Human Tissues

Synopsis

  • Overview of 3D cell culture technologies
  • Impact and importance of 3D cell culture
  • Beyond 3D cell culture as a technique, applications to for the bioengineering of human tissues in vitro
  • Examples of human tissue constructs (eg. skin, intestine) and applications
  • New innovations and developments to further enhancing 3D technology and construction of human tissues in vitro

10:10 am Live Q&A – Ask the Speakers Your Burning Questions

10:30 am Morning Networking Break

  • Live Demo in Virtual Exhibition Hall
  • 1-1 Meetings

Dedicated Roundtable Discussion Chat Room

3D Bioprinting

  • Discussing the benefits of utilizing this technique to model complex physiology with different cell types together
  • What steps are required to standardize protocol with bioprinting?

11:00 am Patient-Derived Scaffolds Uncover Breast Cancer Promoting Properties of the Microenvironment

Synopsis

  • To model and further understand the influence of specific microenvironments we have developed an experimental platform using cell-free patient-derived scaffolds (PDSs) from primary breast cancers infiltrated with standardized breast cancer cell lines
  • Patient-derived scaffolds thus mimics in vivo-like growth conditions and uncovers unique information about the malignancy-inducing properties of tumor microenvironment
  • PDSs can potentially be used in cancer drug design and screening

11:20 am Human Blood–Brain Barrier On-a-Chip

Synopsis

  • Building models of the BBB that recapitulate physiological phenotypes and provides translatable outputs
  • Improving drug delivery by assessing candidate drug barrier penetration and brain exposure

11:40 am Application of MPS in Preclinical Biopharmaceutical Development

  • Norman Peterson Independent Consultant, Biopharmaceutical Development and Life Sciences

Synopsis

  • Opportunities and challenges for incorporating MPS in preclinical development of biologics
  • Maintaining reproducibility in the face of increasing cellular complexity and confounding factors with appropriate biomarkers
  • The incorporation of MPS as an alternative to animal models in preclinical development

12:00 pm Live Q&A – Ask the Speakers Your Burning Questions

12:30 pm Networking Lunch

  • Live Demo in Virtual Exhibition Hall
  • 1-1 Meetings

Dedicated Roundtable Discussion Chat Room

3D Bioprinting

  • Discussing the benefits of utilizing this technique to model complex physiology with different cell types together
  • What steps are required to standardize protocol with bioprinting?

1:00 pm Aracari Biosciences Case Study

Synopsis

Aracari’s vascularized microphysiological systems are leading the way in pre-clinical drug testing. Our team of specialists are driven to help accelerate drug discovery

1:20 pm 3D Bioprinting of Functional Human Tissue & Disease Models for Preclinical Studies

  • MinJae Song Staff Scientist - 3D Bioprinting Core, National Institute of Health Sciences

Synopsis

  • Overview of Tissue Bioprinting Group at NCATS
  • Bioprinting of vascularized tissue platform
    – Ocular tissue (retinal pigment epithelium on “choroid”): modeling wet form age related macular degeneration
    – Skin: modeling atopic dermatitis
    – Omentum: modeling ovarian cancer metastasis
    – Neurovascular Unit: modeling glioblastoma
  • Bioprinting of neural circuit: modeling opioid user disorder
  • Future direction
    – Increasing tissue complexity
    – Developing towards 96 well format for a drug screening platform

1:40 pm Aspiration-Assisted Bioprinting

Synopsis

  • Tissue spheroids have been increasingly used as building blocks for fabrication of tissues, but their precise bioprinting has been a major limitation
  • Demonstrated for the first time that by controlling the location and distance between spheroids we can mediate collective capillary sprouting
  • Aspiration-assisted bioprinting has great potential to develop tissues not only for tissue engineering but also for disease modeling and microphysiological systems

2:00 pm Automated Electrical Stimulation & Optical Force Readout of 3D Bioprinted Human Muscle Tissues in Microplates

Synopsis

  • Discussing a novel device for automated functional readouts such as force and fatigue of 3D bioprinted human skeletal muscle models in microplates
  • Using a 3D bioprinting approach, we have developed a new screening platform for the automated fabrication of functional human skeletal muscle tissue models attached between two posts in microwells, which can be electrically stimulated
  • It is a promising new in vitro exercise model to identify drugs regulating muscle force and fatigue

2:20 pm Diabetes on a Chip

  • Andreas Stahl Professor, Dept. of Nutritional Sciences & Toxicology, UC Berkeley

Synopsis

  • Integrated microphysiological systems for the functional interrogation of insulin sensitivity and glucose homeostasis
  • Obesity/Diabetes models using human stem cell-derived tissues

2:40 pm Live Q&A – Ask the Speakers Your Burning Questions

3:10 pm Virtual Speed Networking

Synopsis

Recreating the face-to-face networking in the virtual world. We will pair you up with fellow attendees to break the ice and make new business relationships!

3:40 pm Use of Engineered Cardiac Tissues for Applications in Cardio Oncology

Synopsis

  • Overview of Biowire II cardiac tissue engineering platform
  • Applications for cardio oncology:
    • for predicting cardiotoxic responses to a chemotherapeutic agent
    • strategies for developing cardioprotective drugs

4:00 pm Advancements in Human Liver Platforms for ADME Studies

  • Niresh Hariparsad Director - Drug Metabolism & Pharmacokinetics Project Leader, Vertex Pharmaceuticals

Synopsis

  • Advancements in Human Liver Platforms for ADME Studies
  • Currently available liver systems and their representative drug metabolism validation datasets
  • Desired functionality for liver platforms to improve their applicability for practical use in the pharmaceutical industry

4:20 pm A Simple High-Throughput Approach Identifies Actionable Drug Sensitivities in Patient-Derived Tumor Organoids

Synopsis

  • Tumor organoids maintain cell-cell interactions, heterogeneity, microenvironment, and drug response of the sample they originate from. Thus, there is increasing interest in developing tumor organoid models for drug development and personalized medicine applications
  • Here we introduce a miniaturized method that allows high-throughput screenings in a format compatible with automation using patient-derived tumor organoids
  • Requiring few tumor cells, we routinely test combination of chemotherapies or targeted therapies directly on primary tumors from patients’ biopsies or surgical samples with the aim to personalize treatment

4:40 pm Human-on-a-Chip Systems for Use in Therapeutic Index Determination & Systemic Toxicity in Pre-Clinical Drug Discovery Application

  • James J. Hickman Professor NanoScience Technology Center, University Central Florida

Synopsis

  • The utilization of multi-organ human-on-a-chip or body-on-a-chip systems for toxicology and efficacy has been suggested as a solution to the lack of good model systems between the single cell level and animal or human systems
  • Application of these systems for ALS, Alzheimer’s, rare diseases, diabetes and cardiac and skeletal muscle mechanistic toxicity will be reviewed
  • The development of in vitro PDPK models that are being used to predict in vivo results will also be presented

5:00 pm Live Q&A – Ask the Speakers Your Burning Questions

5:30 pm Close of Conference Day 2